

Serial No.: 08/402,394 Attorn y Docket No.: 2481.0790-02

APPENDIX B PENDING CLAIMS

U.S. Patent Application No. 08/402,394 Filed: March 10, 1995 Inventors: Michael DORSCHUG et al.

21. (Thrice Amended) A method for the preparation of a mono-Arg-insulin compound of formula II

in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, which comprises:

(a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises a mini-proinsulin compound of the formula:

- (b) liberating said mini-proinsulin compound from said fusion protein;
- (c) folding and forming disulfide bridges in said mini-proinsulin compound;
- (d) incubating said mini-proinsulin compound with trypsin; and
- (e) precipitating the mono-Arg-insulin.

LAW OFFICES
INEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

Serial No.: 08/402,394 Attorney Dock t No.: 2481.0790-02

- 22. (Twice Amended) A method for the preparation of insulin which comprises:
- (a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises a mini-proinsulin compound of the formula:

in which B(1-30) and A(1-21) denote the B and A chains of insulin;

- (b) liberating said mini-proinsulin compound from said fusion protein;
- (c) folding and forming disulfide bridges in said mini-proinsulin compound;
- (d) simultaneously incubating said mini-proinsulin compound with trypsin and carboxypeptidase B; and
 - (e) precipitating the insulin.
- 23. A method as claimed in claim 22, wherein step (d) is carried out in one vessel without having to isolate as an intermediate mono-Arg-insulin of formula II

LAW OFFICES
NEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

Serial No.: 08/402,394

Attorn y Dock t No.: 2481.0790-02

25. (Amended) A method for the preparation of a mono-Arg-insulin compound of formula II

in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, which comprises:

(a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises

bonded via a bridging member,

to a peptide which stabilizes the fusion protein;

- (b) liberating a mini-proinsulin compound from said fusion protein by cleaving the expressed fusion protein resulting from step (a) with cyanogen bromide;
 - (c) folding and forming disulfide bridges in said mini-proinsulin compound;
 - (d) incubating said mini-proinsulin compound with trypsin; and
 - (e) precipitating the mono-Arg-insulin.

LAW OFFICES
INEGAN, HENDERSON,
TARABOW, GARRETT,
& DUNNER, L.L.P.
300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

Serial No.: 08/402,394 Attorn y Docket No.: 2481.0790-02

- 26. (Amended) A method for the preparation of insulin which comprises:
- (a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises

bonded via a bridging member,

to a peptide which stabilizes the fusion protein;

- (b) liberating a mini-proinsulin compound from said fusion protein by cleaving the expressed fusion protein resulting from step (a) with cyanogen bromide;
 - (c) folding and forming disulfide bridges in said mini-proinsulin compound;
- (d) simultaneously incubating said mini-proinsulin compound with trypsin and carboxypeptidase B; and
 - (e) precipitating the insulin.
- 27. A method as claimed in claim 26, wherein step (d) is carried out in one vessel without having to isolate as an intermediate mono-Arg-insulin of the formula II

LAW OFFICES
INEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

Serial No.: 08/402,394 Attorney Dock t No.: 2481.0790-02

31. (Amended) A method for the preparation of insulin, without formation of substantial amounts of insulin Des-B30, comprising:

(a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises

bonded via a bridging member,

-Met-Ile-Glu-Gly-Arg-,

to a peptide which stabilizes the fusion protein;

- (b) liberating a mini-proinsulin compound from said fusion protein by cleaving the expressed fusion resulting from step (a) with cyanogen bromide to produce mini-proinsulin;
- (c) incubating the product formed in step (b) with sodium tetrathionate to form hexa-5-sulfonate;
- (d) simultaneously incubating the S-sulfonate mini-proinsulin formed in step (c) with trypsin and carboxypeptidase; and
 - (e) precipitating the insulin.
- 33. A compound of the formula I

$$B(1-30)-Arg-A(1-21)$$
 (I)

wherein A(1-21) and B(1-30) denote the A and B chains of human insulin.

LAW OFFICES
INECAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

S rial No.: 08/402,394

Attorn y Docket No.: 2481.0790-02

- 34. A nucleic acid sequence encoding the compound of formula I as claimed in claim 33.
 - 35. A vector comprising the nucleic acid sequence of claim 34.
 - 36. A host cell containing the nucleic acid sequence of claim 34.
 - 37. A fusion protein comprising a compound of the formula I

$$B(1-30)-Arg-A(1-21)$$
 (I)

wherein A(1-21) and B(1-30) denote the A and B chains of human insulin, and wherein the compound is bonded via a bridging member

to a peptide which stabilizes the fusion protein.

- 38. A process for the preparation a compound as claimed in claim 33, which comprises:
- a) expressing a DNA sequence encoding the compound of the formula I in a bacterium; and
- b) when the DNA sequence encodes a fusion protein, liberating the compound of formula I from the fusion protein.
 - 39. A method for the preparation of a compound of the formula II

LAW OFFICES
INEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

S rial No.: 08/402,394

Attorney Docket No.: 2481.0790-02

wherein A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, comprising:

a) expressing a DNA sequence encoding the compound of formula I

$$B(1-30)-Arg-A(1-21)$$
 (I)

in a bacterium; and

- b) cleaving the expressed compound of step (a) with trypsin.
- 40. (As Amended on October 19, 1999) A method for the preparation of insulin comprising:
 - a) expressing a DNA sequence encoding the compound of formula I

$$B(1-30)-Arg-A(1-21)$$
 (I)

in a bacterium;

b) cleaving the expressed compound of step (a) with trypsin resulting in the compound of the formula II

LAW OFFICES
INEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000

Serial No.: 08/402,394 Attorney Docket No.: 2481.0790-02

wherein A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin; and

- (c) cleaving the resulting compound of step (b) with carboxypeptidase B.
- 41. The method of claim 40, wherein steps (b) and (c) are carried out in one vessel without having to isolate the intermediate compound of the formula II.
- 42. A method for the preparation of a mono-Arg-insulin compound of the formula II

in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, which comprises:

(a) expressing a DNA sequence encoding a mini-proinsulin compound of the formula:

in a yeast; and

(b) cleaving said mini-proinsulin compound with trypsin.

LAW OFFICES
INEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
300 I STREET, N. W.
SHINGTON, D. C. 20005
202-408-4000